Celcuity Appointed David Gryska to Board of Directors
The Minneapolis-based biotech firm added the veteran life sciences executive to its leadership team.
Updated on Oct. 2, 2026 in People
Live Poll
Does adding experienced leadership to a company's board increase your trust in its future performance?
Celcuity announced the appointment of David Gryska to its Board of Directors as the company transitions into a commercial-stage organization. The move follows the firm's recent receipt of FDA approval for its product REVTORPYK.
Why it matters
The company aims to leverage Gryska's financial and operational expertise to support the upcoming commercial launch of REVTORPYK and ongoing clinical development programs.
David Gryska brings over 35 years of professional experience in the life sciences sector. He has also served on the boards of 8 different public biotechnology companies throughout his career.
The players
David Gryska
He is a veteran life sciences executive who previously served as the Chief Financial Officer for both Celgene Corporation and Incyte Corporation.
Celcuity
Based in Minneapolis, this company is a commercial-stage biotechnology firm currently focused on its drug REVTORPYK and clinical development programs.
The details
Gryska previously held roles as Chief Financial Officer for Incyte Corporation and Celgene Corporation, and served as a partner at Ernst & Young LLP. He is expected to provide strategic guidance as Celcuity plans to advance its drug candidate gedatolisib in additional solid tumor indications.
Timeline
October 2, 2026: Celcuity announced the appointment of David Gryska.
Market Landscape
The addition of an experienced executive reflects a broader trend of biotechnology firms strengthening their governance during the transition from clinical R&D to commercial-stage operations. This strategic hire positions the Minneapolis-based company to better manage the scaling required for new product launches.
Investors and stakeholders should monitor how this leadership addition influences the operational rollout of REVTORPYK. The company's push toward commercial growth may signal upcoming updates regarding the availability and expansion of their drug pipeline.
The takeaway
The hiring of a seasoned CFO signals that Celcuity is prioritizing fiscal and operational discipline to support its market expansion. This shift is a key indicator that the firm intends to move aggressively into the next phase of its drug development lifecycle.
Further reading
For more information on executive changes in the region, visit the People section.
Live Poll
Does adding experienced leadership to a company's board increase your trust in its future performance?
